Rodriguez-Mogeda, Carla
van Lierop, Zoë Y. G. J.
van der Pol, Susanne M. A.
Coenen, Loet
Hogenboom, Laura
Kamermans, Alwin
Rodriguez, Ernesto
van Horssen, Jack
van Kempen, Zoé L. E.
Uitdehaag, Bernard M. J.
Teunissen, Charlotte E.
Witte, Maarten E.
Killestein, Joep
de Vries, Helga E.
Funding for this research was provided by:
Stichting MS Research (MS18-358)
Article History
Received: 19 July 2023
Accepted: 19 September 2023
First Online: 26 September 2023
Declarations
:
: All subjects provided written informed consent to use medical data and materials for scientific research. This study was approved by the institutional ethics committee (Amsterdam UMC Ethics Committee).
: BMJU reports research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva, and Immunic Therapeutics. CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama, Vivoryon. She is editor of Alzheimer Research and Therapy, and serves on editorial boards of Medidact Neurologie/Springer, and Neurology: Neuroimmunology & Neuroinflammation. She had speaker contracts for Roche, Grifols, Novo Nordisk. JK received consulting fees for F. Hoffmann-La Roche, Biogen, Teva, Merck, Novartis and Sanofi/Genzyme (payments to institution); reports speaker relationships with F. Hoffmann-La Roche, Biogen, Teva, Merck, Novartis and Sanofi/Genzyme (payments to institution); adjudication committee of MS clinical trials of Immunic (payments to institution).